{"id":62559,"date":"2026-01-29T04:06:04","date_gmt":"2026-01-29T03:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/"},"modified":"2026-01-29T04:06:04","modified_gmt":"2026-01-29T03:06:04","slug":"tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/","title":{"rendered":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia"},"content":{"rendered":"
\n

\nYUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety<\/i><\/p>\n

\nYUVEZZI was studied in two pivotal Phase 3 trials enrolling<\/i> more than 800 patients,<\/i><\/p>\n

\nincluding the world\u2019s largest and longest safety study for presbyopia eye drops<\/i>1<\/sup><\/i>,2<\/i><\/sup><\/p>\n

\nYUVEZZI achieves miosis from 30-minutes up to 10 hours with one drop daily1<\/sup><\/i><\/p>\n

LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd.<\/a>, a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI\u2122 (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1%, previously known as BRIMOCHOL\u2122 PF, the first and only dual-agent eye drop for the treatment of presbyopia in adults. Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S.3,4,5<\/sup> YUVEZZI is expected to be broadly commercially available in the U.S. in Q2 2026.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe FDA approval of YUVEZZI is based on positive data from two Phase 3 studies. The Phase 3 BRIO I study demonstrated a superior benefit of the combination therapy over the individual actives \u2013 a requirement for FDA approval of a fixed-dose combination.1<\/sup> In the second Phase 3 study, BRIO II, which was vehicle-controlled, YUVEZZI achieved all primary near vision improvement endpoints with statistically significant three-lines or greater improvement in binocular uncorrected near visual acuity (BUNVA) over 8 hours, without the loss of one line or more in binocular uncorrected distance visual acuity (BUDVA).2<\/sup> In addition, YUVEZZI was well-tolerated with no treatment-related serious adverse events observed in the more than 72,000 treatment days monitored in BRIO II, the longest safety study (12 months) conducted in presbyopia to-date.2<\/sup> The most common side effects of YUVEZZI are headache, impaired vision and temporary eye pain or eye irritation.6<\/sup><\/p>\n

\nEye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low.1,2<\/sup> In BRIO II, the rate of reported adverse events of ocular hyperemia (eye redness) was lower in subjects receiving YUVEZZI (2.8%) than carbochol alone (10.7%).2<\/sup><\/p>\n

\n\u201cThe FDA approval of YUVEZZI represents a significant milestone for the millions of people in the U.S. living with presbyopia and its daily frustrations and challenges,\u201d said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. \u201cAs the first FDA-approved dual-agent eye drop for presbyopia, YUVEZZI leverages the mechanisms of carbachol and brimonidine tartrate to deliver sharp near vision with favorable tolerability. People deserve treatments that not only work but also can fit conveniently into their daily lives, and YUVEZZI brings an innovative new option to the presbyopia category. This approval marks the first groundbreaking therapy for Tenpoint Therapeutics aimed at advancing our mission to bring innovation to the aging eye.\u201d<\/p>\n

\n\u201cThe impact of presbyopia is often underestimated, and current solutions like glasses, contacts or surgery have fallen short in meeting the real-world needs of people who struggle with close-up tasks,\u201d said John Hovanesian, M.D., FACS, of Harvard Eye Associates in Laguna Hills, California. \u201cYUVEZZI introduces a novel approach by combining carbachol and brimonidine tartrate in a single daily eye drop that sharpens near vision and maintains tolerability throughout the day. YUVEZZI was intentionally designed to deliver both efficacy and tolerability, which represents an important step forward in delivering a complete, non-invasive option for people with presbyopia.\u201d<\/p>\n

\n\u201cPresbyopia remains a universal and progressive condition that requires individualized management strategies,\u201d said Mile Brujic, OD, FAAO, of Premier Vision Group in Bowling Green, Ohio. \u201cI\u2019m excited that I will be able to offer my patients YUVEZZI\u2122, the first-of-its-kind eye drop well-suited for long-term use. For people seeking a reliable, lifestyle-friendly solution to manage their near vision challenges in aging eyes, YUVEZZI is a valuable and practical advancement.\u201d<\/p>\n

\n\u201cWe\u2019ve been working diligently to bring YUVEZZI to the eye care community and to the millions of adults looking for the optimal solution to address their frustration with presbyopia,\u201d said Carol Kearney, Chief Commercial Officer of Tenpoint Therapeutics. \u201cIt was important to us that we provide an option that fits seamlessly into active, social and professional lifestyles, and we intentionally designed YUVEZZI to offer the right balance of efficacy, tolerability and ease of use.\u201d<\/p>\n

\nAbout Presbyopia<\/b><\/p>\n

\nPresbyopia is the gradual loss of near vision that typically begins around age 45 and significantly affects aging eyes and quality of life.3,4,7,8<\/sup> It is a natural, inevitable part of aging and impacts nearly 128 million people in the U.S. and ~2 billion people worldwide.3,5 <\/sup>Presbyopia affects the lens\u2019 ability to change shape and focus on close objects.9<\/sup> It can also make it difficult to adapt to different levels of ambient illumination, particularly in dim or low-contrast settings.10,7<\/sup><\/p>\n

\nAbout YUVEZZI\u2122 (carbachol and brimonidine tartrate ophthalmic solution<\/strong>) 2.75%\/0.1%<\/b><\/p>\n

\nYUVEZZI\u2122 (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins after the age of 45.6,4<\/sup><\/p>\n

\nThe proposed mechanism of action of this fixed-dose combination of carbachol and brimonidine in presbyopia is pupillary constriction and the creation of a pinhole effect that improves near visual acuity and depth of focus.6<\/sup> Carbachol is a cholinergic agent which produces constriction of the iris sphincter and ciliary body. Brimonidine tartrate, an alpha-adrenergic agonist, blocks contraction of the iris dilator muscle and relaxes tonic contraction of the ciliary muscle, enhancing selectivity for the pupil and increasing bioavailability of carbachol in the aqueous humor.6<\/sup><\/p>\n

\nYUVEZZI Indication and Important Safety Information<\/b><\/p>\n

\nUSE<\/b><\/p>\n

\nYUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% \/ 0.1 is a prescription eye drop for adults with blurry close-up vision due to age.<\/p>\n

\nIMPORTANT SAFETY INFORMATION<\/b><\/p>\n

\nDo not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis).<\/p>\n

\nBefore taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems.<\/p>\n

\nYUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light.<\/p>\n

\nCall your doctor right away if you suddenly have flashes of light, floaters, or vision loss.<\/p>\n

\nDo not let the tip of the vial touch your eye, eyelid, or any other surface.<\/p>\n

\nThe most common side effects of YUVEZZI are headache, impaired vision, and temporary eye pain or irritation. These are not all of the possible side effects of YUVEZZI.<\/p>\n

\nYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov\/medwatch<\/a>, or call 1-800-FDA-1088.<\/p>\n

\nPlease see the Brief Summary for more information.<\/b><\/p>\n

\nPlease see the full Prescribing Information<\/a> for YUVEZZI.<\/p>\n

\nAbout Tenpoint Therapeutics<\/b><\/p>\n

\nTenpoint Therapeutics Ltd. is a global biotechnology company focused on the commercialization of YUVEZZI\u2122 (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.3,5<\/sup> By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.<\/p>\n

\nTo learn more, visit tenpointtherapeutics.com<\/a> and connect on LinkedIn<\/a>.<\/p>\n\n\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n1<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nData on file confirmed from the BRIO I study.<\/p>\n<\/td>\n<\/tr>\n

\n

\n2<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nData on file confirmed from the BRIO II study.<\/p>\n<\/td>\n<\/tr>\n

\n

\n3<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nAmerican Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https:\/\/www.aoa.org\/AOA\/Documents\/Advocacy\/HPI\/presbyopia%20brief%20HPI%20Final.pdf<\/a>.<\/p>\n<\/td>\n<\/tr>\n

\n

\n4<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nNational Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. https:\/\/www.nei.nih.gov\/learn-about-eye-health\/eye-conditions-and-diseases\/presbyopia<\/a>. Accessed January 7, 2026.<\/p>\n<\/td>\n<\/tr>\n

\n

\n5<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nFricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492\u20139.<\/p>\n<\/td>\n<\/tr>\n

\n

\n6<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nYUVEZZI US Prescribing Information<\/p>\n<\/td>\n<\/tr>\n

\n

\n7<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMancil GL, Baily IL, Brookman KE, et al. Optometric clinical practice 2024 guideline care of the patient with presbyopia. American Optometric Association; 2011.<\/p>\n<\/td>\n<\/tr>\n

\n

\n8<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nWolffsohn JS, Leteneux-Pantais C, Chiva-Razavi S, Bentley S, Johnson C, Findley A, Tolley C, Arbuckle R, Kommineni J, Tyagi N. Social Media Listening to Understand the Lived Experience of Presbyopia: Systematic Search and Content Analysis Study. J Med Internet Res. 2020 Sep 21;22(9):e18306.<\/p>\n<\/td>\n<\/tr>\n

\n

\n9<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nGlasser A, Campbell MCW. Biometric, optical and physical changes in the isolated human crystalline lens with age in relation to presbyopia. Vision Research. 1999;39:1991-2015. doi:10.1016\/S0042-6989(98)00283-1. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0042698998002831?via%3Dihub<\/a>.<\/p>\n<\/td>\n<\/tr>\n

\n

\n10<\/sup><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nKandel, H., Khadka, J., Goggin, M. and Pesudovs, K. (2017), Impact of refractive error on quality of life: a qualitative study. Clin. Experiment. Ophthalmol., 45: 677-688.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Brandi Robinson
\n
media@tenpointtx.com<\/a><\/p>\n

\nEye Care Trade Media:<\/b>
Michele Gray
\n
michele@mgraycommunications.com<\/a><\/p>\n

\nInvestors:<\/b>
Ami Bavishi or Nick Colangelo
\n
Gilmartin Group LLC
\n
tenpoint@gilmartinir.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety YUVEZZI was studied in two pivotal Phase 3 trials enrolling more than 800 patients, including the world\u2019s largest and longest safety study for presbyopia eye drops1,2 YUVEZZI achieves miosis from 30-minutes up … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62559","6":"format-standard","7":"category-industry"},"yoast_head":"\nTenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety YUVEZZI was studied in two pivotal Phase 3 trials enrolling more than 800 patients, including the world\u2019s largest and longest safety study for presbyopia eye drops1,2 YUVEZZI achieves miosis from 30-minutes up ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T03:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia\",\"datePublished\":\"2026-01-29T03:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/\"},\"wordCount\":1467,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128284402\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/\",\"name\":\"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128284402\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"datePublished\":\"2026-01-29T03:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128284402\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128284402\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/","og_locale":"en_US","og_type":"article","og_title":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend","og_description":"YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%\/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety YUVEZZI was studied in two pivotal Phase 3 trials enrolling more than 800 patients, including the world\u2019s largest and longest safety study for presbyopia eye drops1,2 YUVEZZI achieves miosis from 30-minutes up ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-29T03:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia","datePublished":"2026-01-29T03:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/"},"wordCount":1467,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/","url":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/","name":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","datePublished":"2026-01-29T03:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260128284402\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI\u2122, the First and Only Combination Eye Drop Approved to Treat Presbyopia"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62559"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62559\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}